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ABSTRACT 
 
The recognition that obstructive disease of the epicardial coronary arteries, causing 
ischemic heart disease, can be treated with a percutaneous coronary intervention (PCI) has 
been a major discovery in cardiology in the last 40 years contributing, in particular, to the 
reduction of mortality associated to acute myocardial infarction (AMI). However, even in the 
era of drug-eluting stent (DES) implantation, a sizable proportion of patients who undergo 
PCI may develop late or very late post-implantation complications, that occur in the form of 
restenosis, neoatherosclerosis and/or in-stent thrombosis. Such complications are clinically 
relevant since they can cause AMI and negatively impact on the outcome. The underlying 
pathophysiological mechanisms are complex but related to inhibition of neointimal 
proliferation by DES that, on the hand, reduces the rate of in-stent restenosis, but, on the 
other hand, causes dysfunctional vessel healing, persistent inflammation, platelet activation 
and adverse immunologic responses. Multiple approaches have been developed or are under 
evaluation to target DES-related complications including pharmacotherapy, procedure-related 
imaging methods, novel stent designs and drug-delivery methods. 
The aim of this review is to provide an update on the latest preclinical, translational 
and clinical pharmacotherapeutic developments in this setting that target novel cellular 
mechanisms and pathways that might contribute to neoatherosclerosis. Due to the importance 
of secondary prevention in the reduction of DES-associated complications, this review also 
provides a short overview of pharmacologic agents that are established or currently being 
investigated in this regard. 
Keywords: coronary restenosis; coronary thrombosis; drug-eluting stents; 
neoatherosclerosis; pharmacotherapy; percutaneous coronary intervention;  
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INTRODUCTION 
While the introduction of drug-eluting stent (DES) technology for the treatment of 
significant culprit lesions due to coronary artery disease (CAD) was able to markedly reduce 
neointimal proliferation, at the same time, a high price was paid in terms of delayed and 
aberrant arterial healing, due to the effects of anti-proliferative drugs eluted by the stent that 
impaired physiological reendothelialization and vascular remodeling.1, 2 Autopsy reports and 
experiments in animal models also showed that persistent fibrin deposition, chronic 
inflammation, and continuous platelet activation characterize delayed arterial healing.3 Most 
of the current DES implants inhibit the mammalian target of rapamycin (mTOR) that is a 
member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family of 
serine/threonine protein kinases.4, 5 Recently, an interaction between the FKBP12.6 cellular 
pathway and canonical mTOR inhibitors was discovered as a major cause of vascular 
permeability and neoatherosclerosis showing that more precise molecular targeting of mTOR 
complex might ameliorate late complications of interventional treatment such as 
neoatherosclerosis.6 Generally, an impaired coronary endothelial function and vasomotion 
associated to DES implantation is characterized by decreased nitric oxide (NO) production, 
loose intercellular junctions and decreased levels of antithrombotic mediators, processes that 
are paralleled by a rapid infiltration, retention, and increased expression of foamy 
macrophages within the neointima of stented segment thus promoting the formation of a new 
atheroma.7 Furthermore, wall shear stress and local hemodynamic forces also play a role in 
restenosis, thrombosis, and platelet activation after stent implantation.8 
In the present review, the role of neoatherosclerosis and other late or very late stent 
complications that occur post-DES implantation are discussed in the context of established 
risk factors and potential therapeutic targets, with emphasis on novel cellular pathways. 
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NEOATHEROSCLEROSIS AS A LATE OR VERY LATE COMPLICATION OF 
INTERVENTIONAL TREATMENT 
Definition of neoatherosclerosis, its incidence and incidence of late stent complications 
As the design in stent technology evolved over time, different profiles of clinical 
complications after stent implantation were observed, corroborated by robust follow-up data. 
Namely, 1st generation DES implants were able to substantially reduce in-stent restenosis 
(ISR) events associated with bare-metal stents (BMS) while increasing the incidence of in-
stent thrombosis (IST).9 Notably, ISR occurs earlier in patients implanted with BMS, 
neointimal hyperplasia (proliferation and migration of vascular smooth muscle cells - VSMC) 
being the prevalent mechanism. 
Furthermore, 2nd generation DES implants were associated with lower rates of IST 
compared to 1st generation DES, however, a different type of complication leading to late or 
very late stent failure came to prominence with newer implants, known as 
“neoatherosclerosis”.10-12 This distinct type of accelerated atherosclerosis of multifactorial 
etiology develops inside of the stented segment of a coronary vessel.13-15 Neoatherosclerosis 
seems to marked by three distinct phases that encompass early infiltration by foamy 
macrophages, in-stent atherosclerotic plaque development, and formation of necrotic core 
plaque with a thin fibrous cap.16 Moreover, among 2nd generation DES implants, differences 
were observed in terms of tissue characteristics in early (<1 year) and late (>1 year) ISR – 
former being mediated mainly by neointimal hyperplasia while neotherosclerosis was the 
dominant mechanism in the latter.17 Specifically, late ISR was characterized by higher 
prevalence of lipid-laden neointima, thin-cap fibroatheroma, neovascularization and 
macrophage infiltration compared to early ISR and it could be inferred that the delayed 
arterial healing associated with DES implants might predispose to neaotherosclerosis. Late 
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stent failure as a consequence of neoatherosclerosis occurs more frequently in DES than 
BMS largely due to stent underexpansion, and nowadays is recognized as a late or very late 
complication of a coronary interventional treatment.18-21 This was confirmed by the autopsy-
based study that revealed significantly higher incidence of neoatherosclerosis in DES (31%) 
compared to BMS (16%) with significantly shorter median stent duration in the former.18 
Moreover, development of neoatherosclerosis in DES implants has been described as a 
“late catch-up” phenomenon due to observation that neointimal growth is highly suppressed 
during the 1st year after DES implantation but then shows continuous progression 
accompanied with rapid deposition of lipid-laden macrophages thus acting as a final common 
pathway of late stent failure.22 Indeed, an optical coherence tomography (OCT) registry-
based study examining very late stent failure mechanisms among early- and new-generation 
DES revealed that three most common causes of very late DES failure were strut 
malapposition (34.5%), neoatherosclerosis (27.6%) and uncovered struts (12.1%).23 A graph 
showing the percentage of atherosclerotic change and neoatherosclerosis incidence in DES 
compared to BMS in relation to implant duration in months is provided in Figure 1. 
Risk factors associated with neoatheroslerosis 
While series of intracoronary imaging studies encompassing intravascular ultrasound 
(IVUS) and OCT along with direct histopathologic analyses from biopsy tissue specimens 
provided a morphological and compositional characterization of neoatherosclerosis, its 
etiology and pathophysiology remain largely unknown.11, 18, 24, 25 Some OCT observations 
suggest that neoatherosclerosis occurs regardless of stent type and is more dependent on focal 
triggers within the vessel that are involved in the formation of vulnerable lesions.26, 27 Some 
relevant differences in pathologic mechanisms between native coronary atherosclerosis and 
in-stent neoatherosclerosis, as well as representative OCT images, are provided in Figure 2. 
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvy036/5115374 by U
niversity of N
ew
 England Libraries user on 09 O
ctober 2018
6 
 
The dominant hypothesis about the neoatherosclerosis formation is based on the 
assumption that neointimal proliferation develops de novo within the stent, independently of 
underlying native plaque; however, this notion is based on a “snapshot” morphological 
lesion analysis and has recently been challenged.28, 29 The pathogenic mechanisms at the basis 
of neoatherosclerosis might indeed be similar to those involved in native atherosclerosis 
progression (e.g., endothelial dysfunction, lipid uptake, inflammation, etc.). An elegant study 
by Taniwaki et al. recently showed a significant association between in-stent 
neoatherosclerosis and the progression of native coronary atherosclerosis, assessed as change 
in minimal lumen diameter (MLD) serially measured within matched coronary segments at 
baseline and 5-year angiographic follow-up.24 This study showed a significantly greater 
reduction in MLD in both target and non-target vessel in patients with in-stent 
neoatherosclerosis than in those without, suggesting a pathogenic link between the two 
processes. These findings appear even more relevant considering the relatively low incidence 
of neoatherosclerosis (i.e., 16% of lesions in the study by Taniwaki) and the need for long-
term follow-up in these patients.24 Importantly, the increased presence of neoatherosclerosis 
is not only associated with individual atherosclerosis risk factors and underlying 
comorbidities, but largely with non-traditional risk factors of which most are inherent to stent 
design, anatomical complexity of the lesion (bifurcations, trifurcations, long lesions, small 
vessels, etc.), local vessel hemodynamics, and PCI-related procedural variables (stent 
underexpansion, malapposition, fracture, flow-limiting dissection, and similar). An 
association of neoatherosclerosis with neovascularization and adjacent lipid plaque has also 
been established.30 A comprehensive overview of risk factors associated with 
neoatherosclerosis is provided in Table 1. 
Hemodynamic alterations within the stented segment of the vessel might also contribute 
to neoatherosclerosis. Endothelial shear stress (ESS), which is the tangential force generated 
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by the friction of the flowing blood on the surface of the vessel wall, affects atherosclerotic 
disease progression in both native and stented coronary arteries.31 Several studies suggest that 
low ESS promotes plaque growth and vulnerable plaque formation in humans.32 As the 
pathogenic mechanisms at the basis of neoatherosclerosis appear to be similar to those 
involved in native atherosclerosis progression (e.g., endothelial dysfunction, lipid uptake, 
inflammation, etc.), it is conceivable that flow dynamics and ESS play an important role in 
the development of neoatherosclerosis after stent implantation. Papafaklis et al. reported an 
inverse correlation between ESS and neointimal hyperplasia in BMS and in first-generation 
DES.33 An OCT study showed that in-stent neoatherosclerosis occurs more often at the inner 
curvature and at the outer waist of a bifurcation, which are typically exposed to low and 
oscillatory shear stress.34 A virtual-histology intravascular ultrasound (VH-IVUS) study by 
Bourantas et al. showed a negative correlation between predominant ESS and the percentage 
of the neointimal necrotic core component, which is indicative of the presence of 
neaotherosclerosis, in BMS.35 
Finally, systemic inflammation and allergic inflammation as reactions to a foreign body 
are biologically important processes that occur after stent implantation and are associated 
with restenosis, stent thrombosis and degree of neointimal lesion burden.36-39  
Pathophysiology of neoatherosclerosis and its clinical implications 
Mechanisms of neoatherosclerosis and accelerated plaque formation after DES 
implantation are poorly elucidated and there is still a substantial lack of knowledge regarding 
the underlying mechanisms and causal factors. Recently, the role of lipid droplet-associated 
proteins such as those belonging to Perilipin family of proteins has been investigated in the 
context of atherogenesis. These proteins have a role in the excess accumulation of 
intracellular lipids and are linked to metabolic diseases, obesity, type 2 diabetes and 
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atherosclerosis.40 Recently, the role of adipophilin, also known as perilipin 2 or adipose 
differentiation-related protein (ADRP) has been implicated in the development of ISR due to 
neoatherosclerosis among patients implanted with 2nd generation DES. Of note, perilipin 
protein levels were significantly higher in peripheral blood mononuclear cells (PBMCs) of 
patients with in-stent neoatherosclerosis and implanted DES compared to patients with native 
CAD.41 
Since rapid formation of lipid-laden neointima and extensive infiltration of foamy 
macrophages at the stent lesion site are histopathologic hallmarks of neoatherosclerosis, as 
previously elaborated, it is plausible that increased lipid retention and accumulation within 
resident macrophages and circulating monocytes that are being increasingly recruited to the 
lesion site are potential mechanisms involved in neoatherosclerosis formation and/or 
progression. Such effect might indeed be mediated by proteins, such as perilipin 2, that are 
involved in the regulation of cytoplasmic lipid droplets within macrophage foam cells and 
storage of cholesteryl esters derived from modified lipoproteins.40, 42 Recently, experimental 
induction of perilipin 2 deficiency and a concomitant increase in extracellular plasma 
cholesterol acceptors such as apolipoprotein A-I (apoA-I) and HDL cholesterol cumulatively 
reduced lipid droplets and cholesterol ester content in cultured macrophages and significantly 
reduced atheroma formation.43  
MicroRNA-based strategies in addressing complications of interventional treatment 
Current drug delivery solutions available with modern stents fail to selectively 
suppress proliferation of VSMCs without a negative impact on the growth of endothelial cells 
(ECs) within the vasculature. To overcome this issue, small non-coding RNA molecules that 
are able to distinctively regulate VSMCs and ECs might provide a viable solution. These 
molecules exert such effects through post-transcriptional silencing, degradation or 
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overexpression of genes and their downstream end-products that are involved in vascular 
remodeling.44, 45 MicroRNAs could be utilized for the selective inhibition of VSMC 
proliferation, platelet activation and improvement of endothelial regeneration after stent 
deployment.46 In fact, a selective miRNA-based strategy was able to markedly reduce 
restenosis, hypercoagulability and improve reendothelialization and vasodilatory response to 
acetylcholine in the preclinical model of vessel injury thus confirming the potential of this 
therapeutic approach in restricting or abolishing restenosis.47, 48 
In the clinical practice, late stent failure due to neoatherosclerosis and stent 
thrombosis is a relevant problem because these events are associated with higher rates of fatal 
and non-fatal acute coronary syndromes (ACS) and of overall poor clinical outcomes.49-51 
Moreover, neoatherosclerosis is a frequent OCT finding in late or very late stent 
thrombosis.14, 23, 52 Due to an increasing number of PCI procedures performed worldwide and 
currently unmet need in ISR prevention, it is expected that significant numbers of late stent 
failure events will occur in the future thus portending poor clinical outcome. Risk factors 
associated with the occurrence of neoatherosclerosis along with available therapeutic 
pathways that could mitigate neoatherosclerosis formation and/or progression are 
summarized in Figure 3.  
 
STENT-BASED STRATEGIES AND PROCEDULAR FACTORS IN THE CONTEXT 
OF NEOATHEROSCLEROSIS 
During the last decade, DES implants have undergone substantial structural 
improvements, including thinner metallic struts and more biocompatible durable or 
biodegradable polymers thus often being labeled as “third-generation” DES. These 
modifications have led to an improved healing response and reduced failure potential 
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compared with first- and second-generation DES.53 Stent design has a significant impact on 
flow dynamics in stented coronary segments. Thick struts affect local ESS, favoring the 
development of flow disturbances with low and oscillatory ESS, which may in turn activate 
the regenerating endothelium toward a pro-inflammatory phenotype and favor lipid uptake.54 
This may induce unfavorable healing response and development of neoatherosclerosis, 
although further studies are needed to confirm this hypothesis. On the other hand, thinner 
struts may improve re-endothelialization and reduce peri-strut inflammation and fibrin 
deposition.55 In addition; the biodegradable polymer type and load may affect healing 
response and development of neoatherosclerosis, by modulating chronic intra-stent 
inflammation. However, there are no conclusive results on the relation between strut 
thickness and use of durable/biodegradable polymers with the formation of 
neoatherosclerosis. A recent OCT study by Guagliumi et al. showed a similar healing 
response after 3 months and incidence of NA after 18 months between a biodegradable 
polymer everolimus-eluting stent and a durable polymer zotarolimus-eluting stent.56 In 
another study, the rate of in-stent neoatherosclerosis within biodegradable polymer biolimus-
eluting stents was similar to bare metal stents, and tended to be lower than in durable polymer 
sirolimus-eluting stents.57 
Furthermore, bioresorbable vascular scaffolds (BVS) were developed to only 
temporarily cover the diseased coronary segment followed by full biodegradation, potentially 
overcoming the long-term issues of metallic stents. However, randomized trials consistently 
observed worse long-term clinical outcomes of the Absorb BVS compared with metallic 
new-generation DES, both in terms of device-oriented adverse events and device thrombosis, 
particularly after 1 year. The international INVEST registry identified neoatherosclerosis as 
one of the main mechanisms underlying very late scaffold thrombosis, being observed in 
about 18% of lesions at 2-year follow-up.58 More recently, Moriyama et al. conducted a study 
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with serial OCT imaging performed at baseline, 1 year, and 5 years after Absorb BVS 
implantation in 20 patients with 22 lesions. Neoatherosclerosis, defined as lipid-laden plaque 
including thin-cap fibroatheroma with or without intimal rupture and/or thrombi, and/or 
calcific plaque with or without neovascularization and/or macro- phage accumulation, was 
identified in 100% of lesions at 5 years after BVS implantation.59 Multiple pathogenic factors 
have been suggested, including endothelial dysfunction, inflammation, and local blood flow 
alterations related to the scaffold strut size (i.e., thick struts), geometry, and large polymer 
load of BVS. Further studies are needed to clarify these potential mechanisms, and to identify 
the incidence of neoatherosclerosis after implantation of BVS other than the Absorb BVS.60 
While the data corroborate that ABSORB BVS is a reasonably safe platform, it did 
not fulfill the promise of abolishing or reducing neoatherosclerosis and/or stent thrombosis. 
However, novel approaches in BVS polymer design that are under development might 
mitigate these late PCI complications. Of note, BVS with polymers based on poly-L-lactic 
acid (PLLA) might support beneficial vascular remodeling in humans without detected 
neoatherosclerosis at 2 years, even in the absence of antiproliferative drugs.61 Previous 
preclinical studies on novel ultrahigh molecular weight amorphous PLLA BVS implants 
demonstrated expansive vascular remodeling in PLLA BVS and this biological phenomenon 
appeared independently of antiproliferative drugs.62, 63 Furthermore, an addition of 
magnesium to BVS was associated with decreased thrombogenicity, less platelet adhesion 
and inflammatory cell deposition in porcine arteriovenous shunt model, compared to BMS.64 
In humans, a 12-month follow-up after implantation of the 2nd generation BVS with 
magnesium backbone showed a favorable safety profile and stable angiographic parameters 
between 6 and 12 months.65 However, caution has to be exercised since De la Torre 
Hernandez et al recently demonstrated that the arterial healing process after implant 
deployment could be more device-specific rather than patient-specific, suggesting that not all 
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BVS scaffolds might act in the same manner in the long-term.66 For this reason, future studies 
on newer generation magnesium- and PLLA-based scaffolds are, indeed, warranted to assess 
their effects on clinical endpoints during longer follow-up, particularly compared to 
established “workhorse” DES platforms.67, 68 
Regarding the procedural PCI factors that might contribute to the formation of 
neoatherosclerosis, an OCT imaging provides accurate stent sizing and guidance of the 
stenting strategy, by providing both information on the lumen dimension and lesion 
characteristics.69 Even more, latest ESC/EACTS guidelines on myocardial revascularization 
support the use of OCT imaging in cases dealing with an in-stent neoatherosclerosis and 
further procedure planning.70 Post-PCI OCT imaging allows strut-level evaluation of the stent 
deployment and provides guidance for stent optimization. OCT is able to identify correctable 
abnormalities related to the stent and the underlying vessel wall, such as stent 
underexpansion, strut malapposition, and geographic plaque miss.70 Stent underexpansion is a 
major predictor of early stent thrombosis or restenosis, however, no definite pathogenic link 
exists between acute strut malapposition and subsequent events.70 In contrast, OCT studies 
investigating the mechanisms of stent thrombosis have consistently identified strut 
malapposition as a frequent underlying finding.23 Whether stent optimization using an OCT 
imaging may impact on the development of neoatherosclerosis at follow-up remains 
unknown, and need to be demonstrated in future studies.  
 
PHARMACOTHERAPEUTIC STRATEGIES IN THE PREVENTION OF 
NEOATHEROSCLEROSIS 
Role of antiproliferative drugs and the mode of drug delivery 
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Sirolimus seems to reduce the amount of positive cell cycle regulators and increase 
the amount of cell cycle inhibitors, leading to inhibited cell migration, proliferation, and 
desensitization of the cells to the effects of low ESS.1 Because durable polymers result in 
long-term drug sequestration within the polymer with prolonged drug delivery over time, this 
may result in long-term endothelial dysfunction. It seems plausible that limiting the duration 
of exposure of the arterial wall to mTOR inhibitors may result in a limited long-term 
endothelial dysfunction and perhaps decreased neoatherosclerosis though this is unproven to 
date.71 
In the absence of definitive clinical data demonstrating differences between durable 
polymer DES (DP-DES) versus bioresorbable polymer DES (BP-DES) in terms of 
neoatherosclerosis, it is worth discussing what some of the advantages of the latter might be 
and why improvement in DES design is still necessary. As alluded to earlier, the genesis of 
late restenosis and neoatherosclerosis remains unknown but studies suggest it may be related 
to long-term effects on endothelium caused by -limus mTOR inhibitors used in the current 
generation DES. Long-term exposure of endothelial cells to sirolimus leads to endothelial 
barrier dysfunction allowing entrance of lipoproteins and immune cells into the arterial wall, 
similar to the pathogenesis of native vessel atherosclerosis.72 Moreover, because drug tissue 
levels tend to decrease dramatically as the polymer degrades, the risk of neoatherosclerosis 
may actually be lower although more work is required to substantiate this claim. However, it 
remains unclear whether metallic surfaces are as biocompatible as polymer-coated surfaces 
(especially those coated with fluorinated polymers). While recent meta-analysis of 
randomized controlled trials showed that BP-DES are non-inferior to DP-DES, their potential 
advantages are yet to be demonstrated.73 
Antiplatelet and lipid-lowering therapy in the context of DES implantation 
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Pharmacotherapeutic secondary prevention encompassing lipid reduction and inhibition 
of platelet activation, pathologic processes that are both implicated in neoatherosclerosis, is 
exceptionally important after DES implantation. The European Society of Cardiology (ESC) 
guidelines clearly emphasize the importance of these therapies after coronary 
revascularization.74-76 The optimal duration of dual antiplatelet therapy (DAPT) with aspirin 
and a thienopyridine (ADP receptor/P2Y12 inhibitor) and/or addition of anticoagulants 
probably need to be calibrated on a personalized assessment of patients’ coronary anatomy, 
comorbidities and ischemic/bleeding risk.75, 77, 78 
Similarly, patients with ACS that underwent PCI are recommended to reach lower targets 
of low-density lipoprotein (LDL) cholesterol compared to conventional patients with 
hyperlipidemia.79 However, these goals are often unmet in population of ACS patients due to 
statin intolerance or refractoriness to LDL cholesterol-lowering despite optimal high-potency 
statin therapy or statin combined with the intestinal cholesterol inhibitor ezetimibe. Due to 
residual cholesterol and inflammatory risk in these patients, therapies that would provide 
additional reduction in circulating levels of LDL cholesterol and proinflammatory mediators 
and would contribute to a greater plaque stabilization are required.80 Recently, proprotein 
convertase subtilisin/kexin type 9 (PCSK9) inhibitors were shown to increase recycling of 
LDL cholesterol receptors, therefore, efficiently lowering concentrations of LDL cholesterol 
in circulation beyond the effects of standard therapy.81 In the context of CAD, GLAGOV trial 
showed that PCSK9 inhibition on top of statin treatment was associated with a significant 
additional reduction of plaque burden in patients with CAD, compared to patients that were 
using statins only.82 This aggressive lipid-lowering treatment with PCSK9 inhibitors might 
have an impact on lipid-related neoatherosclerosis and plaque stabilization since higher levels 
of matured PCSK9 were associated with coronary spotty calcifications in ACS patients and 
this concept was also confirmed in a preclinical study by Goettsch and colleagues.83, 84 
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Finally, precision-tuning of the lipid-lowering therapies might be based on the plaque 
imaging (i.e., assessment of fibrous cap thickness in vulnerable plaque lesions, quantification 
of plaque burden) and geometric characterization of the vessel architecture at lesions of 
interest (i.e., minimal luminal area, etc.) in each individual patient as advanced imaging 
techniques become more routinely used in the clinical practice.85 
 
IL-1/IL-6/CRP pathway 
The inflammation is an important driver of healing responses after stent implantation.86 
Therefore, targeting proinflammatory pathways while exerting immunosuppressive effects 
seems as a reasonable therapeutic approach to prevent in-stent restenosis and late 
complications of interventional treatment.87 The pivotal CANTOS trial demonstrated that 
inflammatory pathogenesis of atherosclerosis is a validated concept showing that the 
inhibition of interleukin-1 beta (IL-1β) with a therapeutic monoclonal antibody canakinumab, 
without affecting lipid levels, in patients with previous acute myocardial infarction (AMI) 
and CRP levels >2 mg/L was able to significantly lower the composite outcome of MI, stroke 
or death by 15% and secondary endpoint that included urgent revascularization by 17%, 
compared to placebo.88 This notion was confirmed in a study by Chibana et al. showing that, 
in patients implanted with the mTOR-inhibitor-eluting stent, sirolimus increased IL-1β 
mRNA expression and increased IL-1β release within coronary artery smooth muscle cells 
(CASMCs) implicating that serum IL-1β levels could serve as a biomarker for DES-
associated coronary endothelial dysfunction.89 Perhaps such effects of inflammation-directed 
pharmacotherapy that inhibits IL-1β pathway could extend to the suppression of 
neoatherosclerosis due to the implicated role of this cellular pathway in foam cell formation 
and induction of interleukin-6 (IL-6) in human endothelial cells.90 Anti-inflammatory agents 
might indeed ameliorate residual risk among patients that survived AMI since standard 
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pharmacotherapy including high-dose statin regimen is often insufficient in preventing 
recurrent ischemic events or death.91 
The pharmacologic blockade of other mediators of inflammation such as interleukin-6 
receptors (IL-6R), CC2 chemokine receptors and CD20 might also prove as viable strategies 
in the future therapeutic targeting of vascular inflammation and atherothrombosis 
prevention.92 
So-called “C-reactive protein (CRP)/IL-6/IL-1 axis” recently became a research hotspot 
in the anti-inflammation secondary prevention pharmacotherapy with agents such as low-
dose methotrexate and low-dose colchicine being currently investigated in clinical trials for 
the purpose of reducing cardiovascular events.93-95 A role of NLRP3 inflammasome that is 
activated by cholesterol crystals and implicated in atherosclerosis has been increasingly 
studied with a potential of well-known “old” agents such as colchicine finding a new role in 
cardiovascular applications.96 A recent study by Vaidya et al. showed that the addition of low 
dose colchicine (0.5 mg/day), which inhibits cholesterol crystal-induced activation of 
inflammasome, to optimal medical therapy was associated to a significant reduction of plaque 
volume at coronary computerized-tomography (CCT) and of hs-CRP levels among patients 
with recent ACS (<1 month), compared to optimal medical treatment only.97 This study 
showed that colchicine might be a valuable addition to secondary prevention armamentarium 
in patients that suffered ACS and because of its anti-inflammatory properties, it is plausible 
that colchicine could mitigate some of the complications of DES implantation. However, to 
establish whether these beneficial effects of colchicine on surrogate end-points translate into 
a benefit on clinical outcomes remains to be investigated.98 
NF – kappa B pathway 
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Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway is an 
intracellular signal transduction system that is implicated in multiple inflammatory disorders, 
cancer proliferation, innate immunity, cellular apoptosis, and differentiation.99 It is a “rapid-
acting” and pleiotropic transcription factor meaning that it is ubiquitously present in cells in 
an inactive form and does not require a de novo protein synthesis for its activation. Activation 
mechanisms of the NF-κB pathway are multiple and include the canonical, non-canonical and 
the atypical activation cascades.100 Canonical pathway of NF-κB activation is mediated by 
Toll-like receptors (TLRs), interleukin-1 receptors (IL-1Rs), tumor necrosis factor receptors 
(TNFRs) and various antigen receptors such as lipopolysaccharides (LPS) from the bacterial 
cell wall and viral antigens.101 Activation of NF-κB dominantly occurs via IkappaB kinase 
(IKK) complex-mediated phosphorylation of inhibitory molecules such as IkappaBalpha that 
seems to play a central role in the initial convergence of most stimuli that can activate NF-κB 
signal transduction.102-104 In the context of inflammatory effects, NF-κB pathway regulates 
proinflammatory cytokine production, leukocyte recruitment, and cell survival thus 
contributing to cellular inflammatory response.105, 107 
Previously, a link between NF-κB pathway and atherosclerosis has been established, 
involving all stages of atheroma development, starting with plaque formation and subsequent 
destabilization and rupture.107, 108 Additionally, NF-κB pathway activation is involved in lipid 
metabolism, foam cell formation, vascular inflammation, proliferation of VSMCs, arterial 
calcification, cardiac fibrosis, and plaque progression making it as a worthwhile therapeutic 
target in cardiovascular disease.109-112 In the preclinical model, inhibition of NF-κB pathway 
abolished induction of adhesion molecules in endothelial cells, impaired macrophage 
recruitment to atherosclerotic lesions and significantly decreased expression of 
proinflammatory cytokines and chemokines in aorta thus clearly demonstrating that NF-κB 
signaling is an important cross-talk mediator of atherosclerosis and its therapeutic blockade 
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could portend myocardial protection.113 In this respect, the use methotrexate, an 
immunosuppressive and antimetabolic agent that inhibits T-cell activation, intracellular 
adhesion molecule expression, folate metabolism and methyltransferase activity and 
selectively downregulates B-cells expression has been recently examined in terms of 
potential cardiovascular pharmacologic applications.114, 115 Importantly, methotrexate blocks 
the binding of interleukin-1β (IL-1β) to interleukin-1 receptors (IL-1Rs) and inhibits 
production of cytokines such as interleukin-4 (IL-4), interleukin-13 (IL-13), interferon 
gamma (IFN-γ) and TNF-α.116, 117 Finally, methotrexate suppresses TNF-induced NF-κB 
pathway activation by inhibition of NF-κB-dependent reporter gene expression.118 Another 
mechanism by which methotrexate decreases basal levels of NF-κB activity is through 
increased expression of long intergenic (noncoding) RNA-p21 levels via DNA-dependent 
protein kinase catalytic subunit (DNA PKcs)-dependent mechanism.119 Furthermore, 
adenosine selectively suppressed TNF-induced NF-κB activation in different cell types.120 
Mechanisms of methotrexate interaction with NF-κB pathway are illustrated in Figure 4. 
Stent-based methotrexate delivery in a porcine coronary artery was able to effectively 
attenuate peristrut inflammation and neointimal hyperplasia.121 Favorable effects of 
methotrexate on the formation of neoatherosclerosis in a rabbit model of atherosclerosis with 
implanted DES were recently reported.122 In humans, a recent clinical study that involved 
patients with elective PCI showed that low dose (5 mg/week) of oral methotrexate 
administration before and after the procedure was safe and no cases of clinical restenosis 
were reported at 9-month follow-up, however, BMSs were used in this setting.123 
Finally, it seems that therapies such as colchicine and methotrexate have a potential of 
lowering cardiovascular risk through immunomodulation.124 If these effects might extend to 
complications of the coronary interventional treatment such as neoatherosclerosis remains to 
be determined. 
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Soluble TREM-1 as a marker of in-stent restenosis and potential pharmacologic target 
Triggering receptor expressed on myeloid cells (TREM)-1 is the transmembrane 
glycoprotein receptor of the immunoglobulin superfamily, involved in activation of 
monocytes/macrophages and neutrophils by signaling through adapter protein DAP12.125 
This protein is implicated in the critical regulation of acute inflammatory responses by 
amplifying Toll-like receptor (TLR)-initiated innate immune responses against microbes and 
by upregulating proinflammatory chemokines and cytokines in response to fungal and 
bacterial antigens.126 Several studies showed that cellular interference with TREM-1 pathway 
conferred a protective effect in the setting of inflammatory bowel disease, septic shock and 
ischemic myocardial injury.127-129 In a study by Boufenzer et al. the soluble form of TREM-1 
(sTREM-1) detected in plasma was a reliable marker of TREM-1 activation and was 
detectable in AMI patients with its concentration level being the independent predictor of 
death.129 In recent times TREM-1 has been marked as one of the orchestrators of the 
inflammatory response that ensues after AMI since TREM-1 deletion or experimental 
modulation by short inhibitory peptide reduced myocardial inflammation, attenuated 
leukocyte recruitment and finally, improved overall heart function and survival in animal 
models.130 During and after the AMI, necrotic cellular fragments and extracellular matrix 
components that are released in the bloodstream produce many damage-associated molecular 
patterns (DAMPS) that, in turn, activate pattern recognition receptors (PRR). In this cascade 
of events, TREM-1 plays an important role since it interacts with multiple PRRs, especially 
with TLR2 and TLR4, receptors with the highest expression levels in the myocardium.126, 131 
Due to these established implications of TREM-1 signaling in cardiovascular pathology, a 
study by Wang et al. enrolled 130 patients with angiography-determined ISR and age- and 
gender-matched control group of 150 patients without ISR that were finally selected among 
the pool of 1683 patients that underwent PCI.132 This study showed that sTREM-1 levels in 
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serum were significantly increased in patients with angiography-determined ISR when 
compared to controls. Furthermore, blockade of TREM-1 with a synthetic inhibitory peptide 
LP17 significantly inhibited while TREM-1-activating antibody promoted increased 
proliferation, migration of VSMCs and cellular inflammation. This study told us two 
important things – sTREM-1 levels in serum might reflect the presence and degree of ISR 
among patients that underwent stent implantation thus serving as a predictive biomarker in 
this setting and on the other hand, pharmacologic inhibition of TREM-1 might help in 
attenuating restenosis progression. Interestingly, TREM-1 expression in macrophages is 
regulated at transcriptional level by NF-kB pathway that was previously elaborated in this 
review and experimental data showed that cellular treatment with inhibitors of NF-kB was 
able to abolish the expression of message of TREM-1 induced by bacterial stimuli.133 
Mechanism of TREM-1 pathway and its interaction with NF-kB pathway are depicted in 
Figure 5. 
Taken together, preclinical, and clinical data on TREM-1 warrant further investigations of 
this peptide in the ACS setting and in the risk management/monitoring for complications 
after stent implantation. 
Future perspectives 
It becomes evident that research directed towards novel stent systems and adjunct 
pharmacologic solutions will mark the upcoming era of cardiovascular science, as we delve 
deeper in the pathophysiology and vascular biology of coronary artery disease and both local 
and systemic immuno-inflammatory responses that are associated with the nature and 
complications of interventional treatment. In this regard, the systemic administration of low-
dose immunosuppressive and anti-inflammatory pharmaceutical agents seems as an attractive 
concept that showed some promise in modifying the course and complications of 
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atherosclerotic disease. How these effects will translate to patient bed and real-life clinical 
outcomes remain to be seen in the upcoming trials, especially those conducted in the 
secondary prevention setting. 
 
CONCLUSIONS 
While tremendous improvements have been made in minimizing the late 
complications of coronary interventional treatment, risks of neoatheroslerosis and late stent 
failure are still present, requiring the skillful precision tailoring of antiplatelet and 
antiinflammation pharmacotherapy combined with the appropriate stent choice placed in the 
correct vessel with correct apposition, size, and expansion in the correctly-selected patient. 
Local delivery of the pharmaceutical agent to the site of the lesion that will secure long-term 
patency with preserved endothelial function remains to be the quest for the interventionalist’s 
Holy Grail. This quest will remain even more complicated with challenges in reducing 
hyperlipidemia, suppressing inflammation, slowing physiological drivers of thrombosis and, 
finally, recognizing the residual cardiovascular risk among patients with a significant 
coronary artery disease and high comorbidity burden that underwent PCI.  
 
Supplementary material: References 51 through 124 are available in the Appendix A. 
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FIGURE LEGENDS 
 
Figure 1. Graph depicting the percentage of atherosclerotic change in drug-eluting stents 
(DES) vs. bare-metal stents (BMS) in relation to implant duration in months (based on the 
autopsy studies). Reproduced based on the Nakazawa et al. JACC: Cardiovascular Imaging, 
2009;2:625-628. 
Figure 2. Basic pathogenic mechanisms of native atherosclerosis and in-stent 
neoatherosclerosis. A-B. Lipid diffusion and inflammatory cell migration through the 
endothelium is similar between native atherosclerosis and in-stent neoatherosclerosis but 
potentially accelerated in the latter due to the presence of an insufficiently regenerated 
endothelium and the effects of drug-induced inhibition of re-endothelialization processes. 
The underlying atherosclerotic plaque might contribute to the growth of neointima both with 
expansion through the stent struts and with the release of proinflammatory factors. 
Furthermore, chronic foreign body reaction to the stent may exacerbate these mechanisms 
thus accelerating neoatherosclerosis progression (red arrows), C-D. Representative 
intracoronary optical coherence tomography (OCT) images showing a native lipid plaque 
within the vessel (C) and a neoatherosclerotic lesion characterized by the lipid-laden 
neointima (D). 
Figure 3. A summary of risk factors associated with neoatherosclerosis and currently 
available pharmacotherapeutic agents that might address pathophysiologic pathways 
associated with the formation and progression of neoatherosclerosis after stent implantation 
due to an acute coronary syndrome. For the making of this figure, illustration elements that 
were kindly provided by the Servier were used. Servier Medical Art is licensed under a 
Creative Commons Attribution V.3.0 Unported License. 
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Figure 4. A scheme showing the effects of methotrexate on NF-kB pathway and pleiotropic 
roles of NF-kB pathway in the pathophysiology of the disease. 
Figure 5. A scheme showing the effects of TREM-1 pathway activation and its implicated 
role in in-stent restenosis and cellular inflammation. TREM-1 blockade by an experimental 
pharmacologic agent is also presented. 
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Table 1. Independent clinical risk factors that are associated with late or very late in-stent 
restenosis due to neoatherosclerosis 
Late or very late neoatherosclerosis (>12 months or >36 months) 
Risk factors PMID 
Presence of peristrut microhemorrhages 27865168 
Increased out-stent plaque volume (OSPVI) 29066157 
Increased mean neointimal thickness (NIT) 23891431 
Stent length  28943494 
Stent fracture 29151488 
„Off-label“ DES usage  23227328 
Localized hypersensitivity reaction 25423451 
DES as an used stent type 22798521, 29066157 
Duration of DES implant >48 months, increased stent age 25613674, 22798521 
DES duration > 20 months 21646494 
BVS duration of 5 years or more 29699614 
Current smoking 22798521 
Chronic kidney disease 25613674, 22798521 
Diabetes mellitus and HbA1c levels >7%, 
Insulin resistance 
24514877, 26413014 
>70 mg/dL of LDL cholesterol at OCT follow-up 25613674 
Absence of ACE-Is or ARBs in post-discharge pharmacotherapy 22798521 
Early neoatherosclerosis (<12 months) 
Arterial hypertension and high pre-stent LDL cholesterol levels 26385044 
Abbreviations: ACE Is-angiotensin-converting enzyme inhibitors; ARBs-angiotensin 2 receptor blockers; BVS-
bioresorbable vascular scaffold; DES-drug-eluting stent; LDL-low-density lipoprotein; PMID-PubMed ID number 
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